Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender offer to acquire Poseida Therapeutics. This move marks a significant…
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
CVS Health and Aetna Allocate $750,000 in Grants to Advance Health Outcomes Across Illinois CVS Health and Aetna Better Health® of Illinois, a CVS Health company, recently announced a combined $750,000 in community grants to organizations dedicated to enhancing health…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…
Astellas Pharma recently announced the approval Gastric Cancer of VYLOYTM (zolbetuximab) by China’s National Medical Products Administration (NMPA) for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the…
OS Therapies Announces $6 Million Private Placement to Fund Clinical Development of OST-HER2 for Osteosarcoma and Other Cancer Indications OS Therapies, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies and antibody-drug conjugates, has successfully closed a private placement…
The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…
Merck, a leading science and technology company, announced plans to invest over €70 million in constructing a new Advanced Materials Development Center (AMDC) at its Shizuoka site in Japan. This brings Merck’s total investment in Shizuoka to over €120 million…
The World Health Organization WHO Academy in Lyon, France, officially opened its doors yesterday with a grand inauguration ceremony. The event was graced by French President Emmanuel Macron, WHO Director-General Dr. Tedros Adhanom Ghebreyesus, and a distinguished assembly of health…
The global market for Antisense & RNAi therapeutics is poised for significant growth, with projections estimating its value at US$5.4 billion in 2024. This market is expected to expand at a compound annual growth rate (CAGR) of 17.8%, reaching a…